Jorge Carlos Santos da Costa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jorge Carlos Santos da Costa has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Jorge Antonio Zepeda Bermudez
Fundação Oswaldo Cruz, Brasil
6 shared publications - Fernanda Manzini
Universidade Federal de Santa Catarina, Brasil
4 shared publications - Silvana Nair Leite
Universidade Federal de Santa Catarina
4 shared publications - Mareni Rocha Farias
Universidade Federal de Santa Catarina
2 shared publications - Norberto Rech
Universidade Federal de Santa Catarina, Brasil
2 shared publications - Adelir Rodrigues da Veiga
Universidade Federal de Santa Catarina, Brazil
1 shared publication
Latest Publications
- Open Access
- 24 August 2026
- Published by Vigilancia Sanitaria em Debate: Sociedade, Ciencia y Tecnologia in Vigilância Sanitária Em Debate: Sociedade, Ciência & Tecnologia
- p. 1-12
Gerenciamento de riscos nas compras públicas de medicamentos oncológicos: estratégia e métodos para mitigação de falhas
Introduction: Public procurement of oncology medicines represents a significant share of healthcare expenditures and plays a crucial role in ensuring universal access to essential therapies. However, the bidding process is subject to failures that compromise efficiency, transparency, and patient safety. Objectives: To develop and apply a risk management (RM) model adapted to the reality of public procurement of oncology medicines, based on nationally and internationally recognized methodologies. Method: Case study of an applied, exploratory, and descriptive nature, with a qualitative approach, grounded in bibliographic and documentary research and direct observations. Techniques such as process mapping, SWOT analysis, brainstorming, and adapted FMEA were used, integrated with the guidelines of ABNT NBR ISO 31000:2018, ABNT NBR IEC 31010:2021, and the Brazilian Federal Comptroller General’s Risk Management Manual (CGU, 2018). Results: A total of 65 hazards were identified in the routines of anticancer drug procurement. The control measures led to a positive reclassification of risks, with a significant shift from the most critical levels to categories of lower impact. Among the 65 identified hazards, 23 were classified as low risk, 35 as medium, 6 as high, and 1 as very high. After the implementation of the control measures, a marked improvement in the risk profile was observed, with 53 events classified as low risk, 9 as medium, 3 as high, and no events as very high risk. These results demonstrate the effectiveness of the actions, achieving the complete elimination of very high risks and a reduction greater than 70% in medium and high risks. Conclusions: The proposed model demonstrated potential to enhance governance, transparency, and efficiency in the public procurement of oncology medicines, in addition to contributing to the sustainability of the SUS.
- 24 August 2026
- Published by Vigilancia Sanitaria em Debate: Sociedade, Ciencia y Tecnologia in Vigilância Sanitária Em Debate: Sociedade, Ciência & Tecnologia
- p. 1-12
Open AccessGerenciamento de riscos nas compras públicas de medicamentos oncológicos: estratégia e métodos para mitigação de falhas
Introduction: Public procurement of oncology medicines represents a significant share of healthcare expenditures and plays a crucial role in ensuring universal access to essential therapies. However, the bidding process is subject to failures that compromise efficiency, transparency, and patient safety. Objectives: To develop and apply a risk management (RM) model adapted to the reality of public procurement of oncology medicines, based on nationally and internationally recognized methodologies. Method: Case study of an applied, exploratory, and descriptive nature, with a qualitative approach, grounded in bibliographic and documentary research and direct observations. Techniques such as process mapping, SWOT analysis, brainstorming, and adapted FMEA were used, integrated with the guidelines of ABNT NBR ISO 31000:2018, ABNT NBR IEC 31010:2021, and the Brazilian Federal Comptroller General’s Risk Management Manual (CGU, 2018). Results: A total of 65 hazards were identified in the routines of anticancer drug procurement. The control measures led to a positive reclassification of risks, with a significant shift from the most critical levels to categories of lower impact. Among the 65 identified hazards, 23 were classified as low risk, 35 as medium, 6 as high, and 1 as very high. After the implementation of the control measures, a marked improvement in the risk profile was observed, with 53 events classified as low risk, 9 as medium, 3 as high, and no events as very high risk. These results demonstrate the effectiveness of the actions, achieving the complete elimination of very high risks and a reduction greater than 70% in medium and high risks. Conclusions: The proposed model demonstrated potential to enhance governance, transparency, and efficiency in the public procurement of oncology medicines, in addition to contributing to the sustainability of the SUS.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 31 (1)
La Política Nacional de Asistencia Farmacéutica: 20 años en defensa de la vida
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 31 (1)
Open AccessLa Política Nacional de Asistencia Farmacéutica: 20 años en defensa de la vida
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 31 (1)
National Pharmaceutical Policy and the Health Economic-Industrial Complex: influences and invisibilities
In 2024, we celebrate the twentieth anniversary of the National Pharmaceutical Policy (PNAF), which involves actions to promote, protect, and restore health, with the population’s access to medicines and their rational use as an essential part of its principles. This intersectoral policy is strategic for including SUS demands in the agenda of other sectors with impacts on the field of Health, including those that are part of the Health Economic-Industrial Complex (CEIS). Given its characteristics, this study aimed to identify the PNAF’s influence in CEIS-related public policies from 2004 to 2024 to improve such policies. We adopted the model developed by Walt and Gilson (1994) to analyze public policies, identifying contexts proposed by Araújo Júnior and Maciel Filho (2001) and the typology of policies proposed by Walt (1994). The results showed the PNAF’s principles and strategic lines in 17 CEIS-and-Health-related sectoral policies over 20 years, with notable invisibilities from 2017 to April 2023.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 31 (1)
Open AccessNational Pharmaceutical Policy and the Health Economic-Industrial Complex: influences and invisibilities
In 2024, we celebrate the twentieth anniversary of the National Pharmaceutical Policy (PNAF), which involves actions to promote, protect, and restore health, with the population’s access to medicines and their rational use as an essential part of its principles. This intersectoral policy is strategic for including SUS demands in the agenda of other sectors with impacts on the field of Health, including those that are part of the Health Economic-Industrial Complex (CEIS). Given its characteristics, this study aimed to identify the PNAF’s influence in CEIS-related public policies from 2004 to 2024 to improve such policies. We adopted the model developed by Walt and Gilson (1994) to analyze public policies, identifying contexts proposed by Araújo Júnior and Maciel Filho (2001) and the typology of policies proposed by Walt (1994). The results showed the PNAF’s principles and strategic lines in 17 CEIS-and-Health-related sectoral policies over 20 years, with notable invisibilities from 2017 to April 2023.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 31 (1)
Two decades of the National Pharmaceutical Policy: a commitment to life
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 31 (1)
Open AccessTwo decades of the National Pharmaceutical Policy: a commitment to life
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 31 (1) , e13002025
A Política Nacional de Assistência Farmacêutica: 20 anos em defesa da vida
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 31 (1) , e13002025
Open AccessA Política Nacional de Assistência Farmacêutica: 20 anos em defesa da vida
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 31 (1) , e14362025
Política Nacional de Assistência Farmacêutica e o Complexo Econômico-Industrial da Saúde: permeações e invisibilidades
Resumo O ano de 2024 marca os vinte anos da vigência da Política Nacional de Assistência Farmacêutica (PNAF), a qual envolve ações de promoção, proteção e recuperação da saúde, tendo o acesso da população aos medicamentos e seu uso racional como parte essencial dos seus princípios. Essa política intersetorial é estratégica para a inclusão das demandas do SUS na agenda dos demais setores com impactos no campo da saúde, incluindo aqueles integrantes do Complexo Econômico-Industrial da Saúde (CEIS). Dadas as suas características, o objetivo do presente estudo foi identificar as permeações da PNAF nas políticas públicas relacionas ao CEIS, entre os anos 2004 e 2024, visando contribuir para o aprimoramento de tais políticas. Adotou-se o modelo desenvolvido por Walt e Gilson (1994) para análise de políticas públicas, com identificação de contextos proposta por Araújo Júnior e Maciel Filho (2001) e tipologia de políticas proposta por Walt (1994). Os resultados evidenciaram permeações dos princípios e eixos estratégicos da PNAF em 17 políticas setoriais relacionadas ao CEIS e à saúde no período de 20 anos, com destacadas invisibilidades no período de 2017 a abril de 2023.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 31 (1) , e14362025
Open AccessPolítica Nacional de Assistência Farmacêutica e o Complexo Econômico-Industrial da Saúde: permeações e invisibilidades
Resumo O ano de 2024 marca os vinte anos da vigência da Política Nacional de Assistência Farmacêutica (PNAF), a qual envolve ações de promoção, proteção e recuperação da saúde, tendo o acesso da população aos medicamentos e seu uso racional como parte essencial dos seus princípios. Essa política intersetorial é estratégica para a inclusão das demandas do SUS na agenda dos demais setores com impactos no campo da saúde, incluindo aqueles integrantes do Complexo Econômico-Industrial da Saúde (CEIS). Dadas as suas características, o objetivo do presente estudo foi identificar as permeações da PNAF nas políticas públicas relacionas ao CEIS, entre os anos 2004 e 2024, visando contribuir para o aprimoramento de tais políticas. Adotou-se o modelo desenvolvido por Walt e Gilson (1994) para análise de políticas públicas, com identificação de contextos proposta por Araújo Júnior e Maciel Filho (2001) e tipologia de políticas proposta por Walt (1994). Os resultados evidenciaram permeações dos princípios e eixos estratégicos da PNAF em 17 políticas setoriais relacionadas ao CEIS e à saúde no período de 20 anos, com destacadas invisibilidades no período de 2017 a abril de 2023.
- Open Access
- 12 December 2025
- Published by Vigilancia Sanitaria em Debate: Sociedade, Ciencia y Tecnologia in Vigilância Sanitária Em Debate: Sociedade, Ciência & Tecnologia
- p. 1-12
Impressão tridimensional de medicamentos: desafios e perspectivas regulatórias
Introduction: The application of three-dimensional printing technology (3DP) has gained notoriety as an alternative to the traditional manufacturing model in the production of medicines, enabling the development of personalized medicines for each patient. Objective: To consolidate the currently available information regarding the regulatory perspectives on the use of 3DP in pharmaceutical manufacturing and to discuss the challenges that must be addressed to enable its broad adoption. Method: This work consists of an integrative literature review in the National Library of Medicine (PubMed) and Web of Science covering the period from December 2019 to December 2024, which approaches the regulatory basis that guide the application of 3DP in the medicine production, in comparison with the traditional production methods, and what are the main gaps and challenges associated with these regulations. Results: The evaluated articles highlight the need of establishing specific regulations focused on the quality and manufacturing sites of medications produced by 3DP, to enable their adoption as an option for supplying personalized medicines. The results reported in this review show that the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Medicines & Healthcare products Regulatory Agency (MHRA) have adopted monitoring of new technologies and advising institutions as a way of enabling the introduction of these medicines in the market and prepare new regulations. Conclusions: The information in this article serves as a preliminary basis to understand the existing regulatory challenges in relation to 3DP of medicines and provide a vision of the scenarios that are being proposed for this technology insertion.
- 12 December 2025
- Published by Vigilancia Sanitaria em Debate: Sociedade, Ciencia y Tecnologia in Vigilância Sanitária Em Debate: Sociedade, Ciência & Tecnologia
- p. 1-12
Open AccessImpressão tridimensional de medicamentos: desafios e perspectivas regulatórias
Introduction: The application of three-dimensional printing technology (3DP) has gained notoriety as an alternative to the traditional manufacturing model in the production of medicines, enabling the development of personalized medicines for each patient. Objective: To consolidate the currently available information regarding the regulatory perspectives on the use of 3DP in pharmaceutical manufacturing and to discuss the challenges that must be addressed to enable its broad adoption. Method: This work consists of an integrative literature review in the National Library of Medicine (PubMed) and Web of Science covering the period from December 2019 to December 2024, which approaches the regulatory basis that guide the application of 3DP in the medicine production, in comparison with the traditional production methods, and what are the main gaps and challenges associated with these regulations. Results: The evaluated articles highlight the need of establishing specific regulations focused on the quality and manufacturing sites of medications produced by 3DP, to enable their adoption as an option for supplying personalized medicines. The results reported in this review show that the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Medicines & Healthcare products Regulatory Agency (MHRA) have adopted monitoring of new technologies and advising institutions as a way of enabling the introduction of these medicines in the market and prepare new regulations. Conclusions: The information in this article serves as a preliminary basis to understand the existing regulatory challenges in relation to 3DP of medicines and provide a vision of the scenarios that are being proposed for this technology insertion.
- 5 September 2025
- Published by Elsevier in Next Research
- Vol. 2 (4)
Preliminary pre-formulation studies of novel mexiletine analogs: Focus on solid-state characterization
- 5 September 2025
- Published by Elsevier in Next Research
- Vol. 2 (4)
Preliminary pre-formulation studies of novel mexiletine analogs: Focus on solid-state characterization
- Open Access
- 13 December 2024
- Published by Vigilancia Sanitaria em Debate: Sociedade, Ciencia y Tecnologia in Vigilância Sanitária Em Debate: Sociedade, Ciência & Tecnologia
- Vol. 12, 1-7
Construindo a soberania sanitária no Mercosul: a experiência do curso de desenvolvimento e produção de vacinas
Introduction: This paper reports on the experience of the Vaccine Development and Production Course, an initiative promoted by Fiocruz within the framework of the MERCOSUR Health Ministers’ Meetings. The experience was developed in the second half of 2023, with the participation of students from Argentina, Brazil, Paraguay, and Uruguay as member states of the bloc and Chile as an associate state. Objective: To support the hypothesis that we will only be able to advance health sovereignty in the field of vaccines if we simultaneously implement sovereignty in terms of strategy and the process of training human resources, articulating the region’s capabilities in a network. Method: This is a report that presents reflections onhealth sovereignty in the production of biological products, based on a training experience that involved the mobilisation of existing capacities at Fiocruz, Instituto Butantan and Nortec, based on synchronous remote classes and personal technical visits. Results: Details of this experience were presented and based on this, we sought to outline appropriate strategies for continuing professional development in the region, with the aim of achieving health sovereignty in terms of regional vaccine production with a view to self-sufficiency. Conclusions: It is noted that despite the language barriers and institutional differences between the bloc and the associated countries, the evaluation carried out at the end of the course confirms the relevance and the need to expand experiences such as the one developed. The need to create capacities in the region to effectively achieve health sovereignty is evident, as well as the importance of incorporating some strategic themes identified by the students to continue the qualification of professionals in the region, in a continuous and permanent training process.
- 13 December 2024
- Published by Vigilancia Sanitaria em Debate: Sociedade, Ciencia y Tecnologia in Vigilância Sanitária Em Debate: Sociedade, Ciência & Tecnologia
- Vol. 12, 1-7
Open AccessConstruindo a soberania sanitária no Mercosul: a experiência do curso de desenvolvimento e produção de vacinas
Introduction: This paper reports on the experience of the Vaccine Development and Production Course, an initiative promoted by Fiocruz within the framework of the MERCOSUR Health Ministers’ Meetings. The experience was developed in the second half of 2023, with the participation of students from Argentina, Brazil, Paraguay, and Uruguay as member states of the bloc and Chile as an associate state. Objective: To support the hypothesis that we will only be able to advance health sovereignty in the field of vaccines if we simultaneously implement sovereignty in terms of strategy and the process of training human resources, articulating the region’s capabilities in a network. Method: This is a report that presents reflections onhealth sovereignty in the production of biological products, based on a training experience that involved the mobilisation of existing capacities at Fiocruz, Instituto Butantan and Nortec, based on synchronous remote classes and personal technical visits. Results: Details of this experience were presented and based on this, we sought to outline appropriate strategies for continuing professional development in the region, with the aim of achieving health sovereignty in terms of regional vaccine production with a view to self-sufficiency. Conclusions: It is noted that despite the language barriers and institutional differences between the bloc and the associated countries, the evaluation carried out at the end of the course confirms the relevance and the need to expand experiences such as the one developed. The need to create capacities in the region to effectively achieve health sovereignty is evident, as well as the importance of incorporating some strategic themes identified by the students to continue the qualification of professionals in the region, in a continuous and permanent training process.
- Open Access
- 1 November 2021
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 26 (11) , 5589-5598
Projeto Integra: fortalecimento da participação social na agenda das políticas, serviços e tecnologias em saúde
Resumo A 16ª Conferência Nacional de Saúde demonstrou o interesse do controle social em intervir sobre as políticas públicas a fim de garantir o direito às tecnologias de saúde. O projeto Integra - Integração das Políticas de Vigilância em Saúde, Assistência Farmacêutica, Ciência, Tecnologia e Inovação em Saúde -, nasce da parceria entre o Conselho Nacional de Saúde, a Escola Nacional dos Farmacêuticos e a Fundação Oswaldo Cruz (Fiocruz), com apoio da Organização Pan-Americana de Saúde (OPAS) com objetivo de fortalecimento da participação e engajamento social na temática e a integração das políticas e práticas de saúde em diferentes setores da sociedade (movimentos sociais, controle social e profissionais de saúde), tendo as diversas etapas relacionadas ao acesso aos medicamentos (pesquisa, incorporação, produção nacional e serviços) como mote principal, no cenário da pandemia de COVID-19. Oferta-se, neste projeto, capacitação para grupos de lideranças nas regiões de saúde e atividades de grande abrangência nacional e política. Espera-se alcançar o estabelecimento de uma rede intersetorial, integrada de lideranças capazes de atuar colaborativamente para a defesa do desenvolvimento da ciência, das políticas públicas, da soberania nacional e do controle social da saúde.
- 1 November 2021
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 26 (11) , 5589-5598
Open AccessProjeto Integra: fortalecimento da participação social na agenda das políticas, serviços e tecnologias em saúde
Resumo A 16ª Conferência Nacional de Saúde demonstrou o interesse do controle social em intervir sobre as políticas públicas a fim de garantir o direito às tecnologias de saúde. O projeto Integra - Integração das Políticas de Vigilância em Saúde, Assistência Farmacêutica, Ciência, Tecnologia e Inovação em Saúde -, nasce da parceria entre o Conselho Nacional de Saúde, a Escola Nacional dos Farmacêuticos e a Fundação Oswaldo Cruz (Fiocruz), com apoio da Organização Pan-Americana de Saúde (OPAS) com objetivo de fortalecimento da participação e engajamento social na temática e a integração das políticas e práticas de saúde em diferentes setores da sociedade (movimentos sociais, controle social e profissionais de saúde), tendo as diversas etapas relacionadas ao acesso aos medicamentos (pesquisa, incorporação, produção nacional e serviços) como mote principal, no cenário da pandemia de COVID-19. Oferta-se, neste projeto, capacitação para grupos de lideranças nas regiões de saúde e atividades de grande abrangência nacional e política. Espera-se alcançar o estabelecimento de uma rede intersetorial, integrada de lideranças capazes de atuar colaborativamente para a defesa do desenvolvimento da ciência, das políticas públicas, da soberania nacional e do controle social da saúde.